Drug Profile
Hepatocyte growth factor - Sosei Heptares
Latest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Osaka University School of Medicine
- Developer Dainippon Sumitomo Pharma; Mitsubishi Tanabe Pharma Corporation; Sosei
- Class Antifibrotics; Growth factors; Neuropsychotherapeutics
- Mechanism of Action Angiogenesis inducing agents; Hepatocyte growth factor stimulants; Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arterial occlusive disorders; Thromboangiitis obliterans; Vascular disorders
Most Recent Events
- 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma